Suzhou, China, April 13, 2022 – Suzhou Smart Nuclide Pharmaceutical Technology Company (“Smart Nuclide”, “Company”), a company specializes in precision radioactive imaging and therapy for oncology indications, has raised 100 million yuan in Series C funding led by Tasly Group, participating by other ventures including ABC International Holdings Ltd., CIITAM Company Ltd. And Qiming Venture. The funds raised will be used to expedite the current programs, including the production and commercialization of SNA001, the Investigational New Drug Application (IND) and clinical trials of SNA002 and SNA006, etc. Meanwhile, the fund will also be used to establish the technology platform for Company’s radiopharmaceuticals, enrich the pipelines, and to expand the cooperation with international leading entities.

Smart Nuclide was founded in 2015, the Company is focusing on the development and application of innovative diagnostic and therapeutic nuclear medicine. Nuclear medicine involves the application of radioactive substances in the diagnosis and treatment of disease, which are two fields that the Company has active research and development. The Company established two R&D platforms including biological agent platform and single-domain antibody based radioactive imaging platform. Based on these two platforms, the Company is able to improve efficiencies and drive innovation. Smart Nuclide currently forms a robust and competitive portfolio of pipelines including rhTSH product, single-domain antibody based imaging radiopharmaceuticals and therapeutical radiopharmaceuticals.

Among the product pipelines of Smart Nuclide, SNA001 is the most advanced product. SNA001 is a recombinant human thyroid‐stimulating hormone (rhTSH) drug, it can rapidly and safely increase the level of serum thyroid‐stimulating hormone, which is an effective and safe alternative to thyroid hormone withdrawal (THW) during the radio Iodine therapy and post-surgical follow-up of thyroid cancer. rhTSH drug has been strongly recommended and updated by relevant clinical guidelines in China and the United States for years. SNA001 is expected to submit New Drug Application (NDA) in 2021, as the first rhTSH drug in China.

Besides, Smart Nuclide currently has two PET Imaging Agent targeting PDL1 and assess the level of tumor Tissue-infiltrating CD8 + T Cells in patients with solid tumors. SNA002 can identify the expression of PDL1 on tumor lesions without competing with PDL1 blocking antibody. SNA002 can guide physicians to personalize treatment based on the very specific type of expression each patient may have, providing a solution to the competitive PDL1 market.

Dr. Xu Tao, Chief Executive Officer & Founder of Smart Nuclide, commented:

Smart Nuclide is committed to develop the “Global Innovation” diagnostic and therapeutic radiopharmaceuticals, the investment will further accelerate our current pipelines to the next stages, bringing innovative and effective diagnosis and therapies to a broad population of patients across a variety of solid tumors.